254 related articles for article (PubMed ID: 18433346)
1. P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity.
Hart SN; Zhong XB
Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):439-52. PubMed ID: 18433346
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy.
Hu L; Zhuo W; He YJ; Zhou HH; Fan L
Pharmacogenet Genomics; 2012 Nov; 22(11):812-9. PubMed ID: 23047293
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation.
Gomes AM; Winter S; Klein K; Turpeinen M; Schaeffeler E; Schwab M; Zanger UM
Pharmacogenomics; 2009 Apr; 10(4):579-99. PubMed ID: 19374516
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy.
Gong L; Zhang CM; Lv JF; Zhou HH; Fan L
Pharmacogenet Genomics; 2017 Sep; 27(9):337-346. PubMed ID: 28731962
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19.
Agrawal V; Huang N; Miller WL
Pharmacogenet Genomics; 2008 Jul; 18(7):569-76. PubMed ID: 18551037
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism.
Hart SN; Wang S; Nakamoto K; Wesselman C; Li Y; Zhong XB
Pharmacogenet Genomics; 2008 Jan; 18(1):11-24. PubMed ID: 18216718
[TBL] [Abstract][Full Text] [Related]
7. Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
Lv J; Hu L; Zhuo W; Zhang C; Zhou H; Fan L
Pharmacogenet Genomics; 2016 Feb; 26(2):80-7. PubMed ID: 26580670
[TBL] [Abstract][Full Text] [Related]
8. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase.
Velazquez MNR; Parween S; Udhane SS; Pandey AV
Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914
[TBL] [Abstract][Full Text] [Related]
9. P450 oxidoreductase deficiency: a disorder of steroidogenesis with multiple clinical manifestations.
Miller WL
Sci Signal; 2012 Oct; 5(247):pt11. PubMed ID: 23092891
[TBL] [Abstract][Full Text] [Related]
10. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro.
Sandee D; Morrissey K; Agrawal V; Tam HK; Kramer MA; Tracy TS; Giacomini KM; Miller WL
Pharmacogenet Genomics; 2010 Nov; 20(11):677-86. PubMed ID: 20940534
[TBL] [Abstract][Full Text] [Related]
11. P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms.
Burkhard FZ; Parween S; Udhane SS; Flück CE; Pandey AV
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):38-50. PubMed ID: 27068427
[TBL] [Abstract][Full Text] [Related]
12. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.
Flück CE; Nicolo C; Pandey AV
Fundam Clin Pharmacol; 2007 Aug; 21(4):399-410. PubMed ID: 17635179
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of the microsomal mixed function oxidases and biological and pathological implications.
Cederbaum AI
Redox Biol; 2015; 4():60-73. PubMed ID: 25498968
[TBL] [Abstract][Full Text] [Related]
14. NADPH P450 oxidoreductase: structure, function, and pathology of diseases.
Pandey AV; Flück CE
Pharmacol Ther; 2013 May; 138(2):229-54. PubMed ID: 23353702
[TBL] [Abstract][Full Text] [Related]
15. Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells.
Heintze T; Klein K; Hofmann U; Zanger UM
Sci Rep; 2021 Jan; 11(1):1000. PubMed ID: 33441761
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
Zanger UM; Schwab M
Pharmacol Ther; 2013 Apr; 138(1):103-41. PubMed ID: 23333322
[TBL] [Abstract][Full Text] [Related]
17. Exploring Novel Variants of the Cytochrome P450 Reductase Gene (
Rojas Velazquez MN; Therkelsen S; Pandey AV
Biomolecules; 2023 Nov; 13(12):. PubMed ID: 38136599
[TBL] [Abstract][Full Text] [Related]
18. Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.
Su J; Gu Y; Pruijn FB; Smaill JB; Patterson AV; Guise CP; Wilson WR
J Biol Chem; 2013 Dec; 288(52):37138-53. PubMed ID: 24196959
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of the cytochromes P450.
Daly AK
Curr Top Med Chem; 2004; 4(16):1733-44. PubMed ID: 15579105
[TBL] [Abstract][Full Text] [Related]
20. Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.
Tomalik-Scharte D; Maiter D; Kirchheiner J; Ivison HE; Fuhr U; Arlt W
Eur J Endocrinol; 2010 Dec; 163(6):919-24. PubMed ID: 20844025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
